CRRT: trattamento della crisi metabolica grave nella maple syrup urine disease

Abstract

Maple syrup urine disease (MSUD) is a rare disorder of the amino acid metabolism that is transmitted as an autosomal recessive trait and is characterized by deficiency of the branched-chain α-keto acid dehydrogenase enzyme complex (BCKDC). Reduced BCKDC activity results in increased plasma concentrations of leucine, isoleucine and valine. Leucine storage is mainly accountable for clinical symptoms within 48 hours of birth, more infrequently later in life. In subsequent years, patients with MSUD can develop acute metabolic decompensation, which may manifest as lethargy and/or coma, along with a high risk of cerebral edema and exitus. Sudden treatment of acute metabolic disorders is required: suppression of catabolism and utilization of amino acids in excess for protein synthesis and prompt removal of accumulated toxic metabolites by extracorporeal techniques (intermittent hemodialysis, continuous renal replacement therapies, peritoneal dialysis) or exchange transfusion. We discuss the case of a 14-year-old patient suffering from MSUD who was hospitalized for acute metabolic failure. The patient was at first treated only with nutritional support, and then with continuous veno-venous hemofiltration (CVVH) for severe neurological involvement.

Keywords

Acute metabolic failure CVVH maple syrup urine disease

Get full access to this article

View all access options for this article.

References

Chuang

DT.

Maple syrup urine disease: it has come a long way. J Pediatr 1998; 132: S17.

Korein

Sansaricq

Kalmijn

et al . Maple syrup urine disease: clinical, EEG, and plasma amino acid correlations with a theoretical mechanism of acute neurotoxicity. Int J Neurosci 1994; 79: 21.

Strauss

Wardley

Robinson

et al . Classical maple syrup urine disease and brain development: principles of management and formula design. Mol Genet Metab 2010; 99: 333–345.

Yoshino

¹, Aoki

Akeda

et al . Management of acute metabolic decompensation in maple syrup urine disease: a multi–center study. Pediatr Int 1999; 41: 132–137.

Brismar

Aqueel

Brismar

et al . Maple syrup urine disease: findings on CT and MR scans of the brain in 10 infants. Am J Neuroradiol 1990; 11: 1219–1228.

Puliyanda

Harmon

Peterschmitt

et al . Utility of hemodialysis in maple syrup urine disease. Pediatr Nephrol 2002; 17: 239–242.

Gouyon

Desgrea

Mousson

Removal of branched–chain amino acids by peritoneal dialysis, continuous arteriovenous hemofiltration, and continuous arteriovenous hemodialysis in rabbits: implications for maple syrup urine disease treatment. Pediatr Res 1994; 35: 357–361.

Phan

Clermont

Merouani

et al . Duration of extracorporeal therapy in acute maple syrup urine disease: a kinetic model. PediatrNephrol 2006; 21: 698–704.

Jouvet

Poggi

Rabier

et al . Continuous venovenous hemodiafiltration in the acute phase of neonatal maple syrup urine disease. J Inher Metab Dis 1997; 20: 463–472.

10.

Wendel

Langenbeck

Lombeck

et al . Exchange transfusion in acute episodes of Maple Syrup Urine Disease – studies on branched–chain amino and keto acids. Eur J Pediatr 1982; 138: 293–296.